Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...
A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
Zacks.com on MSN2h
FDA Accepts J&J's Filing for Autoimmune Disease Drug NipocalimabJohnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, ...
The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.
Zacks.com on MSN2h
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded DealThis week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
Rising Demand for Targeted Therapies and Advancements in Genomic Technologies Propel the Personalized Medicine Biomarkers market to a 14.54% CAGR Akash Anand SNS Insider Pvt. Ltd 415-230-0044 email us ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback